Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs NPCE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NPCE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

NPCE Overall Winner 6-Pillar Tally: BMRA 1 – 4 NPCE (1 Tie) Matrix Metrics: BMRA 3 – 7 NPCE

As of Nov 16, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin), whereas NPCE carries 41.0/100 (SELL) at $7.76 (138.9x Forward P/E, -11.3% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. NPCE 41.0/100 SELL), NPCE captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-11.3% vs. -125.2% operating margin) and revenue trajectory (-15.5% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs NPCE
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
NPCE NASDAQ Head-to-Head Winner
Neuropace, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$7.76
+2.71% 1D
Market Cap $412.6M
TTM Revenue $103M
Forward P/E 138.9x
Beta / 30D Vol 1.32β · 139% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 44.0 Flow 68.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.5%), weak momentum, RSI 22
RSI-14: 22.3 · SMA20: $12.28 · SMA50: $13.06

6-Pillar Scorecard Institutional Category Breakdown (BMRA 1 – 4 NPCE)

Columns: Metric · BMRA · NPCE
1. Valuation Multiples NPCE
Forward P/E N/M 138.9x
Trailing P/E N/M 138.9x
PEG Ratio N/M N/M
EV / Revenue 1.1x 4.6x
2. Growth & Scale NPCE
Revenue Growth (YoY) -8.3% -15.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.3M $103M
Market Cap $6.0M $412.6M
3. Profitability & Quality NPCE
Gross Margin 0.9% 78.9%
Operating Margin -125.2% -11.3%
Net Profit Margin -115.5% -18.4%
Return on Equity (ROE) -113.8% -106.5%
4. Balance Sheet & Cash Flow NPCE
Cash Generation (TTM) -$3.2M -$12M
Cash Flow Margin -73.5% -11.3%
Net Cash / Leverage $1.1M Net Cash $57M Net Debt (5.88x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 123.2% (45th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (3) vs NPCE (7)
Institutional Metric BMRA NPCE Criterion Row Edge
Market Capitalization
Scale
$6.0M $412.6M Larger Scale NPCE
Trailing P/E Ratio
Valuation
N/M 138.9x Lower Multiple NPCE
Forward P/E Ratio
Valuation
N/M 138.9x Lower Multiple NPCE
Revenue Growth (YoY)
Growth
-8.3% -15.5% Higher Growth BMRA
Operating Margin (TTM)
Profitability
-125.2% -11.3% Higher Margin NPCE
Net Profit Margin
Profitability
-115.5% -18.4% Higher Margin NPCE
Return on Equity (ROE)
Capital Efficiency
-113.8% -106.5% Higher ROE NPCE
52-Week Range Position
Momentum
4% ($1–$3) 16% ($5–$20) Stronger Trend NPCE
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 1.32β · 139% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $103M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 78.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · 4.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$12M ($57M Net Debt (5.88x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRA +8.37 pp
BMRA: -28.19% · NPCE: -36.56%
3M Horizon BMRA +29.37 pp
BMRA: -16.97% · NPCE: -46.34%
6M Horizon BMRA +10.48 pp
BMRA: -40.96% · NPCE: -51.44%
1Y Horizon NPCE +7.48 pp
BMRA: -46.86% · NPCE: -39.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue NPCE Revenue BMRA Op. Margin NPCE Op. Margin Margin Leader
FY2019 $10M N/A -46.4% N/A BMRA
FY2020 $10M $40M -41.0% -31.7% NPCE
FY2021 $10M $50M -104.2% -52.5% NPCE
FY2022 $20M $50M -24.0% -89.6% BMRA
FY2023 $10M $70M -135.3% -41.5% NPCE
FY2024 $10M $80M -117.6% -27.1% NPCE
FY2025 $10M $100M -96.7% -16.3% NPCE
FY2026 $0M N/A -119.5% N/A BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NPCE BREAKDOWN
133d in phase · OBV DISTRIBUTION
Current IV 123.2%
IV Percentile 45th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NPCE Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $412.6M market capitalization and -11.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs NPCE Key Questions & Quantitative Answers

As of Nov 16, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.33 (N/M Forward P/E, -125.2% operating margin), whereas NPCE carries 41.0/100 (SELL) at $7.76 (138.9x Forward P/E, -11.3% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. NPCE 41.0/100 SELL), NPCE captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-11.3% vs. -125.2% operating margin) and revenue trajectory (-15.5% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NPCE leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with NPCE at -15.5% YoY revenue growth and +0.0% YoY earnings growth on $103M TTM revenue (78.9% gross margin, -11.3% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.

NPCE screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas NPCE trades at 138.9x Forward P/E, 138.9x Trailing P/E, N/M PEG, and 4.6x EV/Revenue (-11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus NPCE (-106.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, NPCE carries 123.2% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 139% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.